Stada Group
- Dr. Peter Christalla
Dr. Peter Christalla possesses extensive experience in global business development and licensing within the pharmaceutical and biotechnology sectors, currently serving as Senior Manager at STADA Group and Senior Manager at Fresenius Kabi. Prior roles include Project Manager in Cardiac Cell Therapeutics at Miltenyi Biotec GmbH and Team Leader at the University Medical Center Goettingen. Academic qualifications include a PhD in Molecular Biology and Pharmacology from the University Medical Center Hamburg-Eppendorf and a Business Economist degree from FernUniversität in Hagen. Expertise encompasses regenerative medicine, cardiac tissue engineering, biomaterials, stem cell technology, and proteomics.
Location
Frankfurt, Germany
Links
Previous companies
Org chart
Upgrade to view 0 reports
Teams
This person is not in any teams
Offices
This person is not in any offices
Stada Group
12 followers
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.
Ad